Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michelle Bich Tran-Dube is active.

Publication


Featured researches published by Michelle Bich Tran-Dube.


Journal of Medicinal Chemistry | 2011

Structure Based Drug Design of Crizotinib (Pf-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (C-met) Kinase and Anaplastic Lymphoma Kinase (Alk).

J. Jean Cui; Michelle Bich Tran-Dube; Hong Shen; Mitchell David Nambu; Pei-Pei Kung; Mason Alan Pairish; Lei Jia; Jerry Meng; Lee Andrew Funk; Iriny Botrous; Michele McTigue; Neil Grodsky; Kevin Ryan; Ellen Padrique; Gordon Alton; Sergei Timofeevski; Shinji Yamazaki; Qiuhua Li; Helen Y. Zou; James G. Christensen; Barbara Mroczkowski; Steve Bender; Robert Steven Kania; Martin Paul Edwards

Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design. A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3. In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE). Further optimization of the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.


Journal of Organic Chemistry | 2015

Synthesis of Small 3-Fluoro- and 3,3-Difluoropyrrolidines Using Azomethine Ylide Chemistry

Indrawan McAlpine; Michelle Bich Tran-Dube; Fen Wang; Stephanie Scales; Jean Matthews; Michael Raymond Collins; Sajiv Krishnan Nair; Mary Nguyen; Jianwei Bian; Luis Martinez Alsina; Jianmin Sun; Jiaying Zhong; Joseph S. Warmus; Brian T. O’Neill

Here, we report accessing small 3-fluoropyrrolidines and 3,3-difluoropyrrolidines through a 1,3-dipolar cycloaddition with a simple azomethine ylide and a variety of vinyl fluorides and vinyl difluorides. We demonstrate that vinyl fluorides within α,β-unsaturated, styrenyl and even enol ether systems can participate in the cycloaddition reaction. The vinyl fluorides are relatively easy to synthesize through a variety of methods, making the 3-fluoropyrrolidines very accessible.


Organic Letters | 2012

Synthesis of Aryl Ethers via a Sulfonyl Transfer Reaction

Neal W. Sach; Daniel T. Richter; Stephan James Cripps; Michelle Bich Tran-Dube; Huichun Zhu; Buwen Huang; Jean Cui; Scott C. Sutton

A general synthesis of aryl ethers from primary and secondary alcohols and aryl mesylates is presented. The reaction proceeds via a sulfonyl-transfer mechanism. In this paper, we compare the sulfonyl transfer reaction to Mitsunobu ether formation. The reaction can be employed in a multistep synthesis where the aryl mesylate is used as a phenol protecting group and then as an activating group for ether formation. This protecting/activating group strategy is demonstrated using raloxifene as the target.


Journal of Medicinal Chemistry | 2013

Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.

J. Jean Cui; Hong Shen; Michelle Bich Tran-Dube; Mitchell David Nambu; Michele McTigue; Neil Grodsky; Kevin Ryan; Shinji Yamazaki; Shirley Aguirre; Max Parker; Qiuhua Li; Helen Y. Zou; James G. Christensen

The hepatocyte growth factor (HGF)/c-Met signaling axis is deregulated in many cancers and plays important roles in tumor invasive growth and metastasis. An exclusively selective c-Met inhibitor (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (8) was discovered from a highly selective high-throughput screening hit via structure-based drug design and medicinal chemistry lead optimization. Compound 8 had many attractive properties meriting preclinical evaluation. Broad off-target screens identified 8 as a pan-phosphodiesterase (PDE) family inhibitor, which was implicated in a sustained increase in heart rate, increased cardiac output, and decreased contractility indices, as well as myocardial degeneration in in vivo safety evaluations in rats. Compound 8 was terminated as a preclinical candidate because of a narrow therapeutic window in cardio-related safety. The learning from multiparameter lead optimization and strategies to avoid the toxicity attrition at the late stage of drug discovery are discussed.


Journal of Organic Chemistry | 2018

Copper-Catalyzed Chan–Lam Cyclopropylation of Phenols and Azaheterocycles

Joseph Derosa; Miriam O’Duill; Matthew Holcomb; Mark N. Boulous; Ryan Patman; Fen Wang; Michelle Bich Tran-Dube; Indrawan McAlpine; Keary M. Engle

Small molecules containing cyclopropane-heteroatom linkages are commonly needed in medicinal chemistry campaigns yet are problematic to prepare using existing methods. To address this issue, a scalable Chan-Lam cyclopropylation reaction using potassium cyclopropyl trifluoroborate has been developed. With phenol nucleophiles, the reaction effects O-cyclopropylation, whereas with 2-pyridones, 2-hydroxybenzimidazoles, and 2-aminopyridines the reaction brings about N-cyclopropylation. The transformation is catalyzed by Cu(OAc)2 and 1,10-phenanthroline and employs 1 atm of O2 as the terminal oxidant. This method is operationally convenient to perform and provides a simple, strategic disconnection toward the synthesis of cyclopropyl aryl ethers and cyclopropyl amine derivatives bearing an array of functional groups.


Archive | 2004

Aminoheteroaryl compounds as protein kinase inhibitors

Jingjong Jean Cui; Joanne Johnson; Stephen A Kolodziej; Pei-Pei Kung; Xiaoyuan Sharon Li; Jason Qishen Lin; Jerry Jialun Meng; Mitchell David Nambu; Christopher G Nelson; Mason Alan Pairish; Hong Shen; Jennifer Zhang; Michelle Bich Tran-Dube; Allison Walter; Fang-Jie Zhang; Cathleen Elizabeth Hanau; Dilip Bhumralkar; Iriny Botrous; Ji Yu Chu; Lee Andrew Funk; Jr. G. Davis Harris; Lei Jia


Archive | 2005

Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors

Jingrong Jean Pfizer Global R D Cui; Lee Andrew Funk; Lei Pfizer Global R D Jia; Pei-Pei Pfizer Global R D Kung; Jerry Jialun Pfizer Global R D Meng; Mitchell David Nambu; Mason Alan Pairish; Hong Pfizer Global R D Shen; Michelle Bich Tran-Dube


Archive | 2005

Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors

Jingrong Jean Cui; Lee Andrew Funk; Lei Jia; Pei-Pei Kung; Jerry Jialun Meng; Mitchell David Nambu; Mason Alan Pairish; Hong Shen; Michelle Bich Tran-Dube


Journal of Medicinal Chemistry | 2012

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (C-met) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-Ylmethyl)-1H-[1,2, 3]Triazolo[4,5-B]Pyrazin-6-Yl)-1H-Pyrazol-1-Yl)Ethanol (Pf-04217903) for the Treatment of Cancer.

J. Jean Cui; Michele McTigue; Mitchell David Nambu; Michelle Bich Tran-Dube; Mason Alan Pairish; Hong Shen; Lei Jia; Hengmiao Cheng; Jacqui Elizabeth Hoffman; Phuong Thi Quy Le; Mehran Jalaie; Gilles H. Goetz; Kevin Ryan; Neil Grodsky; Ya-Li Deng; Max Parker; Sergei Timofeevski; Brion W. Murray; Shinji Yamazaki; Shirley Aguirre; Qiuhua Li; Helen Y. Zou; James G. Christensen


Archive | 2005

Aminoheteroaryl compounds as protein tyrosine kinase inhibitors

Jingrong Jean Cui; Lee Andrew Funk; Lei Jia; Pei-Pei Kung; Jerry Jialun Meng; Mitchell David Nambu; Mason Alan Pairish; Hong Shen; Michelle Bich Tran-Dube

Collaboration


Dive into the Michelle Bich Tran-Dube's collaboration.

Researchain Logo
Decentralizing Knowledge